cCRADA Collaborations for Nano-related Research and Development

The Nanotechnology Characterization Laboratory (NCL) has amassed a large knowledge base over its more than twenty years providing the Assay Cascade program. The NCL covers a multitude of nanoparticle platforms and biocompatibility data, characterization techniques, and their technical nuances. This knowledge is leveraged to provide sponsor-funded research and development for applications beyond the Assay Cascade’s constraints. It is carried out through a contractor, Cooperative Research and Development Agreement (cCRADA). While the Assay Cascade is restricted to characterization of oncology-based nanomedicines, cCRADA collaborations are not. cCRADA projects cover a broad range of research, including characterization of oncology or non-oncology nanomaterials, mechanistic studies, nanotech formulation projects, and more. NCL collaborates with each sponsor to create a tailored, highly customized research plan for each cCRADA project.

What We Offer

Formulation, optimization, lead selection: design and production of nanoformulations to achieve intended biological endpoints. Our staff has experience with small molecules, biologics, vaccines, and gene therapies.
Mechanistic studies: in vitro and in vivo studies to identify pharmacological or toxicological mechanisms.
Non-oncology nanomaterials: nanomedicines for other therapeutic indications; environmental, health, and safety characterization of engineered nanomaterials, etc.
Bioanalytical assay development: development and validation of assays for lot release, biological activity, bioequivalence, and more.
Instrument optimization: NCL works with instrument developers to improve analytical tools to best meet the needs of the nanotech research community.
And more… Contact us at ncl@mail.nih.gov to see how we can help.

cCRADA Process

cCRADA candidate projects are considered on a case-by-case basis throughout the year. We take several criteria into consideration, including optimal use of NCL’s capabilities and resources and alignment with NCL and NCI’s research interests. We also weigh a project's potential impact to improve nanomedicine research and development. Interested parties can email the NCL (ncl@mail.nih.gov) to discuss their project needs.

For approved projects, work is initiated through a cCRADA with Leidos Biomedical Research, Inc., the operations and technical support contractor for the Frederick National Lab.